Acute Respiratory Distress Syndrome (ARDS)
Partner With Us
Xequel Bio’s aCT1 platform has applications across multiple therapeutic areas. We are seeking strategic partners who could mutually benefit from the use of aCT1 in their areas of expertise. At this time, Xequel Bio is accepting inquiries from partners for our pulmonology program to help bring Aerosolized aCT1 to patients in applicable indications.
Contact us for partnership opportunities.
Investigating indications with significant unmet medical needs
Acute Lung Injury
Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome (ARDS) results in low blood oxygen, and it is usually a secondary development by patients with other severe diseases or injuries. Given the complex patient situation, it can be difficult to identify and treat, with the primary focus being supplying oxygen. Currently, there are no available drugs specifically targeting the treatment of ARDS.
Aerosolized aCT1 peptide is an etiology agnostic respiratory therapeutic with broad potential for the treatment of acute lung injury and other conditions with unmet clinical needs.
Extensive preclinical research has been conducted across multiple models to support the safety and efficacy of aerosolized aCT1.
In preclinical studies, aerosolized aCT1 demonstrated:
Targeted delivery to the desired portion of the lung
Reduction of pulmonary edema and inflammation
Mitigation of pulmonary barrier function
Safe in preclinical studies
Revolutionizing the Way the Body Responds to Injury
Xequel’s aCT1 technology platform is designed to stimulate healing by creating an improved injury response. Our proprietary aCT1 technology facilitates healing as it stabilizes gap and tight junctions to normalize cell-to-cell signaling, control the flow of fluid within tissues, and reduce harmful inflammation.